Anita Mandhare,Satish Biradar,Asha Gurule
Anita Mandhare
Introduction: Azaepothilone B, also known as ixabepilone, is a semi synthetic second generation epothilone B analogue. Azaepothilone B, its derivatives, and analogues, are used for treating advance metastatic breast cance...
Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015) [0.03%]
银屑病小分子药物和抗体的专利分析(2010-2015)
Andrea Chiricozzi,Rosita Saraceno,Lucia Novelli et al.
Andrea Chiricozzi et al.
Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is increasingly being discussed, particularly when compared to past decades. The use of biologic agents has profoundly changed the history of ...
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update [0.03%]
大麻素受体2(CB2)激动剂和拮抗剂：专利更新
Paula Morales,Laura Hernandez-Folgado,Pilar Goya et al.
Paula Morales et al.
Introduction: Modulation of the CB2 receptor is an interesting approach for pain and inflammation, arthritis, addictions, neuroprotection, and cancer, among other possible therapeutic applications, and is devoid of centra...
Damian Rolfe,Jayson Parker,Max Morgan
Damian Rolfe
Introduction: This paper explores whether, and under what circumstances, a biosimilar approved in the United States under the Biologics Price Competition and Innovation Act (hereafter 'BPCIA') can be patented. The possibi...
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015) [0.03%]
糖尿病治疗中艾塞那肽及其类似物专利盘点（2012-2015）
Eun Ji Park,Sung Mook Lim,Kang Choon Lee et al.
Eun Ji Park et al.
Introduction: Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting inj...
Piperazine derivatives for therapeutic use: a patent review (2010-present) [0.03%]
Piperazine衍生物的药物应用专利回顾（2010-至今）
Anuj K Rathi,Riyaz Syed,Han-Seung Shin et al.
Anuj K Rathi et al.
Introduction: Piperazine, a six membered nitrogen containing heterocycle, is of great significance to the rational design of drugs. This moiety can be found in a plethora of well-known drugs with various therapeutic uses,...
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015) [0.03%]
己内酯途径抑制剂作为神经病治疗药物的专利回顾（2012-2015）
Dénes Zádori,Gábor Veres,Levente Szalárdy et al.
Dénes Zádori et al.
Introduction: The proven pathological alterations in the kynurenine pathway of tryptophan metabolism, either in preclinical models of neurological and psychiatric disorders or in human samples themselves, elicited numerou...
Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792 [0.03%]
治疗性聚合物纳米颗粒及其制备和使用方法：对WO2015036792专利的评估
Sailu Sarvagalla,Hsing Pang Hsieh,Mohane Selvaraj Coumar
Sailu Sarvagalla
Evaluation of the patent application WO2015036792 claiming therapeutic polymeric nanoparticles loaded with AZD1152-hqpa (aurora kinase inhibitor), and methods of making and using same for the treatment of cancer, is described. The claimed p...
Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation [0.03%]
含硫氧亚胺取代喹唑啉的药物组合物US 20150005278(A1)：专利评价
Kaalin Gopaul,Neil A Koorbanally
Kaalin Gopaul
Mnk1 and Mnk2 are protein kinases responsible for phosphorylating eIF4E, a eukaryotic initiation factor responsible for initiating translation. Inhibiting Mnk1 and Mnk2 could therefore play a role in treating metabolic diseases such as canc...
Treatments and compositions for attention deficit hyperactivity disorder: a patent review [0.03%]
注意力缺陷多动障碍的治疗方法和药物：专利回顾
Antonio Molina-Carballo,Ana Checa-Ros,Antonio Muñoz-Hoyos
Antonio Molina-Carballo
Introduction: Attention deficit and hyperactivity disorder (ADHD) is a syndrome that affects children prior to 12 years of age. ADHD manifests as inappropriate behavior and learning difficulties and, in many cases, it per...